Carmegliptin

Overview

Carmegliptin (RO-4876904) is an orally active and potent DPP IV inhibitor with a human DPP IV IC 50 of 6.8 nM. Carmegliptin binds to the S1 pocket of DPP IV, blocks the degradation of GLP 1 , potentiates endogenous GLP 1, increases plasma insulin levels, alleviates hyperglycemia, improves glucose tolerance. Carmegliptin acts as a substrate for human P glycoprotein without inhibiting the transporter, shows low in vitro cell permeability. Carmegliptin can be used for the research of type 2 diabetes, non insulin dependent diabetes mellitus.

Application

Products | Products > Disease Areas > Type 2 Diabetes | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Glucose Metabolism | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Dipeptidyl Peptidase | Products > Signaling Pathways > GLP Receptor | Products > Signaling Pathways > P-glycoprotein

Product Information

• Catalog No.: HY-10289
• CAS No.: 813452-18-5
• Molecular Formula: C20H28FN3O3
• Molecular Weight: 377.45
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source